Shree Ganesh Remedies develops certain form of Cyclo-Propyl derivative

Shree Ganesh Remedies Limited said that the company has developed a certain form of Cyclo-Propyl derivative, which is presently being imported by most of the manufacturers in India for the synthesis of drugs such as Naltrexone and Buprenorphine.

The API intermediates and fine chemicals producer said that the Cyclo-Propyl derivative has been developed in its laboratory located at Ankleshwar in Gujarat.

Shree Ganesh Remedies said that its product will serve domestic as well as global markets.

Shree Ganesh Remedies develops certain form of Cyclo-Propyl derivative
Shree Ganesh Remedies develops certain form of Cyclo-Propyl derivative. Photo courtesy of Darko Stojanovic from Pixabay.

The Gujarat-based company expects to begin commercial production of the Cyclo-Propyl derivative by the first week of next month.

Shree Ganesh Remedies stated: “As it a basic building block we expect that it will find usage over a wide range of applications and will attract huge volumes in upcoming years.”


Discover more from Business-News-Today.com

Subscribe to get the latest posts sent to your email.

See also  Teva launches generic version of Delzicol delayed-release capsules in US
Total
0
Shares
Related Posts
Read More

Bayer to fully acquire US cell therapy company BlueRock Therapeutics

Bayer acquisition of BlueRock Therapeutics : Bayer will take full ownership in US cell therapy company BlueRock Therapeutics for an enterprise value of up to $1 billion, as per the latest pharma acquisition news. Headquartered in Cambridge, BlueRock Therapeutics develops engineered cell therapies in the fields of neurology, cardiology, and immunology using its proprietary induced […]

The post Bayer to fully acquire US cell therapy company BlueRock Therapeutics appeared first on PharmaNewsDaily.com.

Read More

Sobi to acquire US pharma company Dova Pharmaceuticals in $915m deal

Sobi acquisition of Dova Pharmaceuticals : Swedish Orphan Biovitrum (Sobi) has signed a deal worth up to $915 million to acquire Dova Pharmaceuticals, a US pharma company, in a move to become a major player in hematology and orphan diseases and also for expanding its footprint in the US. Shareholders of Dova Pharmaceuticals will be […]

The post Sobi to acquire US pharma company Dova Pharmaceuticals in $915m deal appeared first on PharmaNewsDaily.com.